Last updated: July 29, 2025
Introduction
European Patent No. EP2504353, granted by the European Patent Office (EPO), delineates rights surrounding specific pharmaceutical compounds. This patent’s scope, claims, and position within the current patent landscape are critical for pharmaceutical innovators, legal professionals, and competitors seeking strategic patent analysis and freedom-to-operate assessments.
This report presents a comprehensive dissection of the patent’s scope and claims, positioning within the broader landscape of related drugs and patents, and identifies potential opportunities and threats delineated by the patent’s protective breadth.
Patent Overview and Background
EP2504353, titled "Substituted Pyrazolyl-Pyrimidines for Treatment of Diseases", was filed with priority claims dating back to 2010, indicating early R&D phases occurred prior to application. The patent relates broadly to novel chemical entities, specifically substituted pyrazolyl-pyrimidines, which exhibit therapeutic properties, notably as kinase inhibitors.
The patent’s core objective is to protect specific chemical structures that modulate biological pathways associated with inflammatory, oncological, or neurological diseases. It claims innovation in chemical composition, methods of production, and therapeutic uses.
Scope and Claims Analysis
Scope of the Patent
The scope primarily hinges on the chemical class of substituted pyrazolyl-pyrimidines, their derivatives, and their use in treating various diseases. The patent emphasizes:
- Chemical Structure Framework: The claims encompass compounds with certain core structures and permissible substituents, facilitating a broad coverage of chemical variations within the defined class.
- Pharmacological Targeting: The compounds’ utility as kinase inhibitors, particularly targeting kinases implicated in cancer and inflammation.
- Methods of Treatment: Therapeutic methods applying the compounds to treat diseases such as cancer, autoimmune disorders, and neurological conditions.
Claims Breakdown
The patent contains multiple claims, subdivided into independent and dependent claims. The following exemplifies key elements:
Claim Scope Assessment:
- The scope is relatively broad, covering various chemical modifications within the core scaffold.
- The functional claims extend protection to both the compounds themselves and their therapeutic applications, aligning with modern patenting practices to secure comprehensive commercial rights.
Claim Strengths and Limitations
Strengths:
- Broad chemical genus claims that encompass numerous derivatives, deterring generic or minor structural modifications.
- Inclusion of method claims enhances strategic protection and hinders design-around strategies.
Limitations:
- The claims may face challenge if prior art discloses similar structures or uses, especially in closely related kinase inhibitors.
- The breadth could potentially be contested if certain claims overlap substantially with existing patents.
Patent Landscape Context
Key Surrounding Patents and Literature
The patent landscape for kinase inhibitors, especially pyrazolyl and pyrimidine derivatives, is dense, with extensive filings across major jurisdictions. Notable entities like Pfizer, Novartis, and Merck have filed numerous related patents.
Prior art references include:
- US patents on similar heterocyclic compounds with kinase inhibitory activity.
- Scientific publications detailing synthesis and biological activity of substituted pyrazolyl-pyrimidines.
The EP2504353 patent distinguishes itself through specific substituents, synthesis methods, or claimed therapeutic uses, which may provide inventive non-obviousness over some prior disclosures.
Legal Status and Challenges
The patent was granted, indicating examination found the claims sufficiently novel and inventive. Nonetheless, potential challenges could arise based on:
- Existence of prior art revealing similar compounds.
- Claims scope being too broad and susceptible to non-obviousness arguments.
Any legal disputes or licensing negotiations will hinge on the specific chemical scope and how closely the patent claims overlap with competing patent rights.
Complementary Patents
The landscaping trend indicates a proliferation of secondary patents (e.g., secondary use or process patents) that could complement or fence off specific territories within the scope of EP2504353. These are vital for sustenance of market exclusivity.
Implications for the Industry
The broad claims covering chemical compounds and therapeutic methods offer robust protection but could face validity challenges if prior art overlaps significantly. Strategic players will assess:
- The patent’s enforceability within jurisdictions beyond the EPO.
- Potential inventiveness of claimed derivatives.
- Opportunities for licensing or designing around effective alternative structures.
The landscape’s saturation necessitates continuous monitoring for innovations that may circumvent or expand upon the scope defined by EP2504353.
Key Takeaways
- EP2504353 provides broad protection over substituted pyrazolyl-pyrimidines, with claims covering both the compounds and their therapeutic application.
- Its scope includes numerous chemical variants, offering a significant fortress against minor structural modifications.
- The patent landscape surrounding kinase inhibitors is competitive, and overlapping prior art may challenge certain claims’ novelty or inventiveness.
- The strategic value lies in the patent’s breadth, but ongoing vigilance is necessary for potential legal challenges and licensing opportunities.
- For stakeholders, understanding this patent enables effective positioning—either leveraging its scope, developing design-arounds, or navigating licensing negotiations.
FAQs
1. How broad is the chemical scope of EP2504353?
The patent encompasses a wide class of substituted pyrazolyl-pyrimidines defined by variable substituents, capturing numerous derivatives intended for kinase inhibition.
2. Does the patent protect both the chemical compounds and their therapeutic use?
Yes. The claims cover the compounds themselves and methods of using them in treating specific diseases such as cancer and inflammatory conditions.
3. What are potential challenges to the patent’s validity?
Challenges could stem from prior art disclosures of similar compounds or formulations, especially if overlapping with known kinase inhibitors or heterocyclic compounds.
4. How does EP2504353 compare with other patents in the kinase inhibitor space?
Its broad protective scope sets it apart, but the densely populated landscape of kinase patents requires strategic IP management to maintain effective exclusivity.
5. What is the strategic significance of this patent for pharmaceutical companies?
It offers a strong patent foundation for drug development targeting kinase pathways, enabling exclusivity, licensing, or partnership opportunities within its protected chemical space.
References
[1] European Patent Office. Patent EP2504353 – Substituted pyrazolyl-pyrimidines for treatment of diseases.
[2] Scientific literature on kinase inhibitors, heterocyclic compounds.
[3] Patent landscape reports on kinase inhibitor IP portfolios.
[4] European Patent Register and legal status records.
